Read by QxMD icon Read

mantle cell lymphoma ara c

Dai Chihara, Chan Y Cheah, Jason R Westin, Luis E Fayad, Maria A Rodriguez, Fredrick B Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Andre Goy, Fernando Cabanillas, Hagop Kantarjian, Larry W Kwak, Michael L Wang, Jorge E Romaguera
Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival in younger adults with mantle cell lymphoma (MCL). However, there have been no long-term follow-up results for patients treated with these regimens. We present long-term survival outcomes from a pivotal phase II trial of rituximab, hyper-fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with methotrexate and cytarabine (R-HCVAD/MA). At 15 years of follow-up (median: 13·4 years), the median failure-free survival (FFS) and overall survival (OS) for all patients was 4·8 years and 10·7 years, respectively...
January 2016: British Journal of Haematology
Nobuya Hiraoka, Jiro Kikuchi, Takahiro Yamauchi, Daisuke Koyama, Taeko Wada, Mitsuyo Uesawa, Miyuki Akutsu, Shigehisa Mori, Yuichi Nakamura, Takanori Ueda, Yasuhiko Kano, Yusuke Furukawa
Bendamustine has shown considerable clinical activity against indolent lymphoid malignancies as a single agent or in combination with rituximab, but combination with additional anti-cancer drugs may be required for refractory and/or relapsed cases as well as other intractable tumors. In this study, we attempted to determine suitable anti-cancer drugs to be combined with bendamustine for the treatment of mantle cell lymphoma, diffuse large B-cell lymphoma, aggressive lymphomas and multiple myeloma, all of which are relatively resistant to this drug, and investigated the mechanisms underlying synergism...
2014: PloS One
S Dietrich, A Boumendil, H Finel, I Avivi, L Volin, J Cornelissen, R J Jarosinska, C Schmid, J Finke, W B C Stevens, H C Schouten, M Kaufmann, C Sebban, M Trneny, G Kobbe, L M Fornecker, J Schetelig, E Kanfer, T Heinicke, M Pfreundschuh, J L Diez-Martin, D Bordessoule, S Robinson, P Dreger
BACKGROUND: Autologous stem-cell transplantation (autoSCT) is considered a standard treatment of non-frail patients with mantle cell lymphoma (MCL), but little is known about outcome of MCL patients relapsing after autoSCT. We therefore sought to analyse the outcome after autoSCT failure and the efficacy of a rescue stem-cell transplantation (SCT) in this setting. PATIENTS AND METHODS: Patients with MCL were eligible if they had relapsed after autoSCT performed between 2000 and 2009...
May 2014: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Wolfgang Lamm, Johannes Drach, Barbara Kiesewetter, Christoph C Zielinksi, Marius E Mayerhöfer, Leonhard Müllauer, Markus Raderer
PURPOSE: The management of patients with mantle cell lymphoma (MCL) not eligible for stem cell transplantation in relapse after receiving standard approaches remains challenging, and the search for active and tolerable regimens is still warranted. PATIENTS AND METHODS: We have retrospectively analyzed activity of rituximab (375 mg/m(2) i.v. day 1), Ara-C (1,000 mg i.v. total twice daily on day 2) and oxaliplatin (130 mg/m(2) i.v. day 3) (R-ADOx) in 12 patients (median age 69 years) with relapsed MCL...
October 2013: Journal of Cancer Research and Clinical Oncology
S H Bernstein, E Epner, J M Unger, M Leblanc, E Cebula, R Burack, L Rimsza, T P Miller, R I Fisher
BACKGROUND: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic and community-based practices, a phase II study of this regimen was conducted by SWOG. PATIENTS AND METHODS: Forty-nine patients with advanced stage, previously untreated MCL were eligible...
June 2013: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Martin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, Wolfram Klapper, Niclas Vogt, Marie-Helene Delfau-Larue, Grit Hutter, Chan Cheah, Annalisa Chiappella, Sergio Cortelazzo, Christiane Pott, Georg Hess, Carlo Visco, Umberto Vitolo, Pavel Klener, Igor Aurer, Michael Unterhalt, Vincent Ribrag, Eva Hoster, Olivier Hermine
Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in virtually all cases. Clinically, MCL displays an aggressive course, with a continuous relapse pattern and a median survival of only 3-7 years. However, a subset of up to 15% long-term survivors has recently been identified with a rather indolent clinical course. In general, conventional chemotherapy is only palliative and the median duration of remissions is only 1-2 years...
April 2013: Leukemia & Lymphoma
M Witzens-Harig, G Hess, J Atta, M Zaiss, G Lenz, C Scholz, R Repp, M Reiser, C Pott, H Pelz, P La Rosée, H Kirchner, P Kiewe, U Keller, C Buske, A Viardot, M Dreyling
In most patients, mantle cell lymphoma (MCL) shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. In the current study generation of the European MCL Network, the addition of high-dose Ara-C to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimen followed by myeloablative consolidation achieved a significant improvement of progression-free survival in younger patients. In elderly patients, rituximab maintenance led to a marked prolongation of remission duration...
November 2012: Annals of Hematology
Silvia Castegnaro, Carlo Visco, Katia Chieregato, Martina Bernardi, Elena Albiero, Cristina Zanon, Domenico Madeo, Francesco Rodeghiero
Bendamustine and cytosine arabinoside (ara-c) are commonly used cytotoxic agents with unique mechanisms of action. We have previously reported a striking additive cytotoxic effect of the consecutive combination of bendamustine and ara-c in mantle cell lymphoma (MCL) cell lines. In the present study, cell lines of follicular lymphoma (DOHH-2), chronic lymphocytic leukemia/lymphoma (EHEB), diffuse large B-cell lymphoma (SU-DHL-4), T-cell leukemia/lymphoma (JURKAT and KARPAS-299) and MCL (JEKO-1 and GRANTA-519) were exposed to the two single drugs or the drugs combined, given simultaneously and consecutively...
November 2012: Leukemia & Lymphoma
Martin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, Elena Hartmann, Itziar Salaverria, Grit Hutter, Patricia Perez-Galan, Gael Roue, Christiane Pott, Steven Le Gouill, Sergio Cortelazzo, Simon Rule, Georg Hess, Francesco Zaja, Umberto Vitolo, Michal Szymczyk, Jan Walewski, Vincent Ribrag, Michael Unterhalt, Olivier Hermine, Eva Hoster
Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in virtually all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of up to 15% long-term survivors has been identified with a rather indolent clinical course. Advanced stage disease is usually apparent already at first clinical manifestation; in general, conventional chemotherapy is only palliative and median duration of remissions is only 1-2 years...
December 2011: Leukemia & Lymphoma
D Rolland, M Raharijaona, A Barbarat, R Houlgatte, C Thieblemont
PURPOSE: Mantle cell lymphoma (MCL) is a chemoresistant lymphoma overexpressing the class pi glutathione-S-transferase (GST-pi). The nuclear localisation of GST-pi is induced by chemotherapy and is correlated to cell resistance. In this study, the effect of the Agaricus bisporus lectin (ABL), a GST-pi nuclear transfer inhibitor, on the chemosensitivity of MCL cells was investigated. METHODS: The proliferation of three MCL cell lines was evaluated in the presence of doxorubicin (DOX), cisplatin (CDDP), cytarabine (Ara-C), gemcitabine (GEM) or bortezomib with or without ABL pre-treatment...
October 2010: Anticancer Research
Dejan Radeski, Gavin M Cull, Michael Cain, L Peter Hackett, Kenneth F Ilett
PURPOSE: We report that hemodialysis clears Ara-U from the blood after high-dose Ara-C treatment in a patient with lymphoma and end-stage renal failure. METHODS: The patient received two doses of Ara-C 1 g/m(2) 24 h apart and was hemodialyzed at about 6 h after each dose and subsequently as per her usual dialysis schedule. Multiple blood samples were collected after dosing. Blood and dialyzate were also collected from the dialysis circuit during a second identical treatment cycle...
April 2011: Cancer Chemotherapy and Pharmacology
Martin Dreyling, Wolfgang Hiddemann
PURPOSE OF REVIEW: Mantle cell lymphoma is a distinct subtype of malignant lymphoma, which displays an aggressive clinical course with a continuous relapse pattern and the worst long-term outcome of all B-cell lymphoma. Conventional-dosed chemotherapy achieves only temporary responses with a median duration of remissions of only 1-2 years. RECENT FINDINGS: Addition of monoclonal antibodies has improved initial response but duration of response remained almost uninfluenced...
September 2008: Current Opinion in Oncology
Mars B van 't Veer, Daphne de Jong, Marius MacKenzie, Hanneke C Kluin-Nelemans, Marinus H J van Oers, Jose Zijlstra, Anton Hagenbeek, Wim L J van Putten
Mantle cell lymphoma (MCL) has a dismal outcome when treated with conventional chemotherapy. This single arm phase 2 study evaluated intensive consolidation treatment of patients with newly diagnosed MCL up to the age of 65 years, responsive to R-CHOP (rituximab, cyclophosphamide, oncovin, adriamycin, prednisolone). Endpoints for evaluation were toxicity, failure-free survival (FFS) and overall survival (OS). Eighty-seven patients were treated with three cycles of R-CHOP. Sixty-six patients responded to R-CHOP with at least a partial response, 62 continued protocol treatment with high-dose cytarabine (Ara-C; 2000 mg/m(2), bid...
February 2009: British Journal of Haematology
Yuhong Zhou, Liang Zhang, Jorge Romaguera, Kay Delasalle, Xiaohong Han, Xin Du, Larry Kwak, Qing Yi, Michael Wang
Mantle cell lymphoma (MCL), an aggressive non-Hodgkin's lymphoma characterized by t(11; 14)(q13; q32) chromosomal translocation and overexpression of cyclin D1, has the worst prognosis among all lymphomas. Recent advances in biology, genetics, and immunology have supported the development of immunotherapy in MCL. Rituximab monotherapy in MCL has limited activity. It is more effective when used in combination with chemotherapy such as R-CHOP, R-hyperCVAD/MTX-Ara-C, or R-FCM as front-line or salvage therapy for mantle cell lymphoma...
February 2008: American Journal of Hematology
Peter Dreger, Michael Rieger, Bärbel Seyfarth, Manfred Hensel, Michael Kneba, Anthony D Ho, Norbert Schmitz, Christiane Pott
BACKGROUND AND OBJECTIVES: Autologous stem cell transplantation (ASCT) is effective in mantle cell lymphoma (MCL). We investigated whether incorporation of rituximab into the high-dose regimen might further improve the results of ASCT in patients with MCL. DESIGN AND METHODS: In a prospective phase II study, patients with newly diagnosed MCL were treated with a sequential dose-escalating therapy comprising standard chemotherapy for remission induction, intensive ara-C-containing chemotherapy for mobilization of stem cells, and myeloablative therapy followed by ASCT...
January 2007: Haematologica
D S Ritchie, J F Seymour, A P Grigg, A W Roberts, R Hoyt, S Thompson, J Szer, H M Prince
The hyper-CVAD + rituximab (R) programme consists of fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone + R alternating with high-dose methotrexate + cytarabine (HD MTX/ARA-C) + R. This regimen, when used as initial therapy for patients under 65 years of age with previously untreated mantle cell lymphoma (MCL), results in remission rates of > 85% with a median event-free survival (EFS) of > 50 months, but with a pattern of continuous relapse out to 60 months. We performed a study of hyper-CVAD + R, followed by consolidative peripheral blood progenitor cells autograft [autologous stem cell transplant (AuSCT)] with high-dose busulfan and melphalan (Bu/Mel) conditioning, in patients with responsive disease...
February 2007: Annals of Hematology
Satoshi Hara, Taiji Yokote, Toshikazu Akioka, Satoko Oka, Takeshi Yamano, Motomu Tsuji, Toshiaki Hanafusa
A 59-year-old man presented in January 2003 with generalized lymphadenopathy. An inguinal lymph node biopsy showed mantle cell lymphoma (MCL). After four courses of Rituximab-CHOP therapy were administered, complete response (CR) was achieved. However, in August 2003, he presented with neck lymphadenopathy and was found to have relapsed. Several salvage therapies (ESHAP, Hyper-CVAD/MTX-ara-C) were administered, but CR was not achieved. After two courses of single-agent chemotherapy with CPT-11 (40 mg/m2) were administered on days 1, 2, 3, 8, 9, and 10, CR was achieved...
May 2005: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Christiane Pott, Carsten Schrader, Stefan Gesk, Lana Harder, Markus Tiemann, Thorsten Raff, Monika Brüggemann, Matthias Ritgen, Benedikt Gahn, Michael Unterhalt, Martin Dreyling, Wolfgang Hiddemann, Reiner Siebert, Peter Dreger, Michael Kneba
To evaluate the prognostic impact of minimal residual disease (MRD), quantitative real-time polymerase chain reaction (RQ-PCR) of clonal IGH rearrangements was performed in 29 patients with mantle cell lymphoma (MCL) treated with high-dose radiochemotherapy and autologous stem cell transplantation (ASCT). Fourteen of 27 patients evaluable for MRD after ASCT achieved complete clinical and molecular remission, whereas 13 patients had detectable MRD within the first year after ASCT. Molecular remission after ASCT was strongly predictive for improved outcome, with a median progression-free survival (PFS) of 92 months in the MRD-negative group compared with 21 months in the MRD-positive group (P < ...
March 15, 2006: Blood
John F Seymour, Andrew P Grigg, Jeff Szer, Richard M Fox
BACKGROUND: Based on in vitro synergism, the combination of cytarabine (ara-C) and cisplatin is the basis of many salvage regimens for patients with aggressive non-Hodgkin lymphoma (NHL). However, patients with previously refractory disease are significantly less likely to respond, stimulating the search for novel salvage regimens. In vitro, fludarabine enhances the cytotoxicity of both ara-C and cisplatin, increasing ara-C incorporation into DNA and inhibiting repair of platinum/DNA adducts, suggesting that the combination of cisplatin, fludarabine, and ara-C (PFA) may have clinical utility...
February 1, 2002: Cancer
A M Senderowicz
The majority of hematopoietic malignancies have aberrancies in the retinoblastoma (Rb) pathway. Loss in Rb function is, in most cases, a result of the phosphorylation and inactivation of Rb by the cyclin-dependent kinases (cdks), main regulators of cell cycle progression. Flavopiridol, the first cdk modulator tested in clinical trials, is a flavonoid that inhibits several cdks with evidence of cell cycle block. Other interesting preclinical features are the induction of apoptosis, promotion of differentiation, inhibition of angiogenic processes and modulation of transcriptional events...
January 2001: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"